Adverse effects of baricitinib in comparison to methotrexate in the treatment of severe alopecia areata

Pranam Swapan Dash; Lubna Khondker; Mostaque Mahmud; Marufa Shahrin; Wasi Deen Ahmed; Saikat Das Rony

doi:10.18203/2320-6012.ijrms20262161

Authors

Pranam Swapan Dash Department of Dermatology and Venereology, Bangladesh Medical University, Dhaka, Bangladesh
Lubna Khondker Department of Dermatology and Venereology, Bangladesh Medical University, Dhaka, Bangladesh
Mostaque Mahmud Department of Dermatology and Venereology, Bangladesh Medical University, Dhaka, Bangladesh
Marufa Shahrin Department of Dermatology and Venereology, Bangladesh Medical University, Dhaka, Bangladesh
Wasi Deen Ahmed Department of Dermatology and Venereology, Bangladesh Medical University, Dhaka, Bangladesh
Saikat Das Rony Department of ENT, Narayanganj Sadar (Victoria) Hospital, Narayanganj, Bangladesh

DOI:

https://doi.org/10.18203/2320-6012.ijrms20262161

Keywords:

Alopecia areata, SALT score, Adverse effects of baricitinib, Adverse effects of methotrexate

Abstract

Background: Existing therapies for alopecia areata often yield suboptimal results and have some associated side effects. Janus kinase (JAK) inhibitors are a recent advancement in the treatment of alopecia areata which are treatment resistant or severe.

Methods: This analytical observational study was conducted in the department of Dermatology and Venereology of Bangladesh Medical University to compare the adverse effects of baricitinib and methotrexate in the treatment of severe alopecia areata. About 84 patients of alopecia areata were divided into two groups. Patients of group A were treated with oral baricitinib and group B were treated with oral methotrexate for 6 months.

Results: The most common adverse effects noted in baricitinib group was upper respiratory tract infection 14.3% and hyperlipidaemia was 11.9% of patients and in methotrexate group was nausea 28.6%, and elevated liver transaminase was 16.7 % patients. Serum transaminase (ALT) elevation was significantly raised from baseline to after 6 months (40.21±19.29, p<0.001) in methotrexate group, whereas there was no significant change (33.53±19.86, p=0.506) in baricitinib group. There was statistically significant change before and after treatment in serum creatinine (0.88±0.12, p=0.004) in baricitinib group, compared to no significant change in methotrexate group (p=0.222). There was significant rise in total cholesterol, triglyceride and LDL after 6 months of treatment with baricitinib and these results were statistically significant (p<0.001).

Conclusions: After 6 months of treatment, baricitinib has proven its superiority over methotrexate in terms of safety in the treatment of severe alopecia areata.

References

Lee HH, Gwillim E, Patel KR, Hua, T, Rastogi S, Ibler E. Epidemiology of alopecia areata, ophiasis, totalis, and universalis: A systematic review and meta-analysis. J Ame Acad Dermatol. 2020;82(3):675-82.

Numata T, Irisawa R, Mori M, Uchiyama M, Harada K. Baricitinib therapy for moderate to severe alopecia areata: A retrospective review of 95 Japanese patients. Acta Dermato Venereolog. 2024;104:adv18348.

Dillon KL. A comprehensive literature review of jak inhibitors in treatment of alopecia areata. Clin Cosmet Investigat Dermatol. 2021;14:91-714.

Taylor S, Korman NJ, Tsai T, Shimomura Y, Feely M, Dutronc Y, et al. Efficacy of baricitinib in patients with various degrees of alopecia areata severity: post-hoc analysis from BRAVE AA1 and BRAVE AA2. Dermatol Ther. 2023;13(12):3181-91.

Hammerschmidt M, Mulinari Brenner F. Efficacy and safety of methotrexate in alopecia areata. Anais Brasileiros de Dermatol. 2014;89:729-734.

Khondker L, Sultana A, Khan MSI. The usefulness and wellbeing of Tofacitinib in the treatment of Alopecia Areata. J Arm For Medi Coll Banglad. 2022;18(1):43-7.

Sedeh FB, Michaelsdóttir TE, Henning MAS, Jemec GBE, Ibler KS. Comparative efficacy and safety of janus kinase inhibitors used in alopecia areata: a systematic review and meta-analysis. Acta Dermato-Venereolog. 2023;3:adv00855.

Olamiju B, Friedmann A, King B. Treatment of severe alopecia areata with baricitinib. J Am Acad Dermatol. 2019;5(10):892-4.

Rudnicka L, Arenbergerova M, Grimalt R, Ioannides D, Katoulis AC, Lazaridou E, et al. European expert consensus statement on the systemic treatment of alopecia areata. J Europ Acad Dermatol Venereol. 2024;38(4):687-94.

Kabir S, Savitha B, Ananta K. Which is the Ideal JAK Inhibitor for Alopecia Areata-Baricitinib, Tofacitinib, Ritlecitinib or Ifidancitinib-Revisiting the Immunomechanisms of the JAK Pathway? Ind Dermatol Online J. 2023;14(4):465-74.

Ali EN, Owais R, Sheikh A & Shaikh, AJ. Olumniant (Baricitinib) oral tablets: An insight into FDA-approved systemic treatment for Alopecia Areata. Ann Medi Surg. 2022;80:104157.

Freitas E, Guttman-Yassky E, Torres T. Baricitinib for the treatment of alopecia areata. Drugs. 2023;83(9):761-70.

Fleischmann R, Schiff M, Van Der Heijde D, Ramos-Remus C, Spindler A, Stanislav M. Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment. Arthr Rheumatol. 2017;69(3):506-17.

Phan K, Ramachandran V, Sebaratnam DF. Methotrexate for alopecia areata: A systematic review and meta-analysis. J Am Acad Dermatol. 2018;80(1):120-127.e2.

Olsen EA, Hordinsky MK, Price VH, Roberts JL, Shapiro J, Canfield D, et al. Alopecia areata investigational assessment guidelines–Part II. J Am Acad Dermatol. 2004;51(3):440-7.

Kavak A, Yeşildal N, Parlak AH, Gökdemir G, Aydoǧan I, Anul H, et al. Alopecia areata in Turkey: Demographic and clinical features. J Europ Acad Dermatol Venereol. 2008;22(8):977-81.

Uzuncakmak T, Engin B, Serdaroglu S, Tuzun Y. Demographic and clinical features of 1,641 patients with alopecia areata, alopecia totalis, and alopecia universalis: a single-center retrospective study. Skin Append Dis. 2021;7(1):8-12.

Olamiju B, Friedmann A, King B. Treatment of severe alopecia areata with baricitinib. J Am Acad Dermatol. 2019;5(10):892-4.

Zakaria A, Paul H, Islam M, Islam A. Epidemiologic Profile of Alopecia areata-Study in a tertiary hospital in Bangladesh. Associa Phys Bangladesh. 2009;20:30-4.

Ahmed HE, Ahmed SH. Comparative efficacy of oral Janus kinase inhibitors and biologics in adult alopecia areata: A systematic review and Bayesian network meta‐analysis. J Europ Acad Dermatol Venereol. 2024;38(5):835-43.

Senna M, Mostaghimi A, Ohyama M, Sinclair R., Dutronc Y, Wu WS, et al. Long‐term efficacy and safety of baricitinib in patients with severe alopecia areata: 104‐week results from BRAVE‐AA1 and BRAVE‐AA2. J Europ Acad Dermatol Venereol. 2024;38(3):583-93.

King B, Ko J, Forman S, Ohyama M, Mesinkovska N, Yu G, et al. Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study. J Ame Acad Dermatol. 2021;85(4):847-53.

Alsufyani HS, Rawas WA, Alsufyan SS. The effect of mehotrexate in the treatment of alopecia areata. The Egypt J Hospit Medi. 2017;67(2):599-604.